Matrix Pharmaceutical, Inc.

Syntex (u.s.a.) Inc.

Biomedicines, Inc.

Matrix Pharmaceuticals, Inc.

Richard Maskiewicz

Richard E Jones

Kathleen V Roskos

Dennis M Brown

Deborah M Lidgate

Keith Washco

Leo Gu

George Trager

Victoria M Knepp

Shawnya K Michaels

Methods and compositions are provided for the treatment of a host suffering from a cellular proliferative disease. In the subject methods, antiproliferative agents are administered in a substantially non-aqueous gel delivery vehicle comprising at least one polar organic solvent in combination with one or more thickening agents. The subject methods and compositions provide for the enhanced efficacy of regionally or locally administered antiproliferative proliferative agents.

Gel delivery vehicles for anticellular proliferative agents

Stable, aqueous pharmaceutical formulations of human nerve growth factor (NGF) in aqueous isotonic solutions, buffered to maintain the pH from about 4.5 to about 6.0, and optionally containing a carrier such as human serum albumin are provided. Also provided are aqueous NGF formulations suitable for lyophilization and subsequent reconstitution in which rhNGF is admixed with sugars, optionally HSA, and buffer. The formulations are useful for the treatment of Alzheimer's disease and other neuronal disorders.

Pharmaceutical formulations of nerve growth factor

An improved diluent for the preparation of cisplatin suspensions from a lyophilized powder is provided. The diluent contains a pharmaceutically acceptable nonionic surfactant, which improves the accuracy and homogeneity of the therapeutic formulation. The suspension may be used directly, or may be used in preparing gel formulations for direct injection into a neoplastic lesion or surrounding tissue.

Process and composition for therapeutic cisplatin (CDDP)

Methods and compositions are provided for the treatment of a host with a cellular proliferative disease, particularly a neoplasia. In the subject methods, a pharmaceutically acceptable, substantially anhydrous, injectable semi-solid composition which acts as a depot for a cytostatic agent, is administered to a lesion of the disease, particularly intralesionally. The subject compositions comprise a water immiscible, fatty acid ester matrix and a cytostatic agent.

Methods and compositions for the treatment of a host with a cellular

Growing community of inventors

Sunnyvale, CA, United States of America

Richard Maskiewicz